他卡西醇靶向肿瘤微环境中的抑制性髓系细胞。
Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.
机构信息
Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.
Department of Medicine, Indiana University-Simon Cancer Center, Indianapolis, IN, USA.
出版信息
Oncoimmunology. 2018 May 7;8(10):e1072672. doi: 10.1080/2162402X.2015.1072672. eCollection 2019.
Abstract
Infiltrating myeloid derived suppressor cells and tumor-associated macrophages (TAMs) are important components of the immunosuppressive tumor microenvironment. We recently reported that tasquinimod, which binds to S100A9, impairs both infiltration and function of these cells. Here we discuss the underlying mechanisms responsible for targeting multiple suppressive populations and the modulation of the tumor microenvironment.
摘要
浸润性髓系来源的抑制性细胞和肿瘤相关巨噬细胞（TAMs）是免疫抑制性肿瘤微环境的重要组成部分。我们最近报道称，tasquinimod 与 S100A9 结合，可损害这些细胞的浸润和功能。在这里，我们讨论了靶向多种抑制性群体的潜在机制以及肿瘤微环境的调节。
相似文献
1
Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.
Oncoimmunology. 2018 May 7;8(10):e1072672. doi: 10.1080/2162402X.2015.1072672. eCollection 2019.
2
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
J Immunother Cancer. 2015 Dec 15;3:53. doi: 10.1186/s40425-015-0098-5. eCollection 2015.
3
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.
4
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005319.
5
Mechanisms of action of tasquinimod on the tumour microenvironment.
Cancer Chemother Pharmacol. 2014 Jan;73(1):1-8. doi: 10.1007/s00280-013-2321-8. Epub 2013 Oct 27.
6
Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer.
Oncotarget. 2017 Apr 10;8(33):54173-54186. doi: 10.18632/oncotarget.17013. eCollection 2017 Aug 15.
7
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.
Oncoimmunology. 2016 Feb 18;5(6):e1145333. doi: 10.1080/2162402X.2016.1145333. eCollection 2016 Jun.
8
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12.
9
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.
Int J Cancer. 2014 Mar 1;134(5):1077-90. doi: 10.1002/ijc.28449. Epub 2013 Sep 23.
10
Metabolomic profiling of tumor-infiltrating macrophages during tumor growth.
Cancer Immunol Immunother. 2020 Nov;69(11):2357-2369. doi: 10.1007/s00262-020-02622-8. Epub 2020 Jun 9.
引用本文的文献
1
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.
Cell Oncol (Dordr). 2025 Feb 25. doi: 10.1007/s13402-025-01051-y.
2
2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives.
Molecules. 2024 Mar 11;29(6):1241. doi: 10.3390/molecules29061241.
3
S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.
Commun Med (Lond). 2024 Feb 20;4(1):22. doi: 10.1038/s43856-024-00444-8.
4
: Pathogenesis and therapeutic targets.
MedComm (2020). 2023 Sep 4;4(5):e353. doi: 10.1002/mco2.353. eCollection 2023 Oct.
5
S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment.
Heliyon. 2023 Jan 29;9(2):e13294. doi: 10.1016/j.heliyon.2023.e13294. eCollection 2023 Feb.
6
Role of myeloid-derived suppressor cells in tumor recurrence.
Cancer Metastasis Rev. 2023 Mar;42(1):113-142. doi: 10.1007/s10555-023-10079-1. Epub 2023 Jan 14.
7
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
J Hematol Oncol. 2022 May 18;15(1):61. doi: 10.1186/s13045-022-01282-8.
8
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Pharmacol Ther. 2022 Jul;235:108114. doi: 10.1016/j.pharmthera.2022.108114. Epub 2022 Feb 2.
9
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.
10
The Enigma of Low-Density Granulocytes in Humans: Complexities in the Characterization and Function of LDGs during Disease.
Pathogens. 2021 Aug 27;10(9):1091. doi: 10.3390/pathogens10091091.
本文引用的文献
1
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.
2
S100A9 interaction with TLR4 promotes tumor growth.
PLoS One. 2012;7(3):e34207. doi: 10.1371/journal.pone.0034207. Epub 2012 Mar 28.
3
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
J Clin Oncol. 2011 Oct 20;29(30):4022-8. doi: 10.1200/JCO.2011.35.6295. Epub 2011 Sep 19.
4
Antigen specificity of immune suppression by myeloid-derived suppressor cells.
J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12.
5
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
J Exp Med. 2010 Oct 25;207(11):2439-53. doi: 10.1084/jem.20100587. Epub 2010 Sep 27.
6
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.
PLoS Biol. 2009 Apr 28;7(4):e97. doi: 10.1371/journal.pbio.1000097.
7
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506.
8
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
J Exp Med. 2008 Sep 29;205(10):2235-49. doi: 10.1084/jem.20080132. Epub 2008 Sep 22.
9
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
J Immunol. 2008 Oct 1;181(7):4666-75. doi: 10.4049/jimmunol.181.7.4666.
10
Altered macrophage differentiation and immune dysfunction in tumor development.
J Clin Invest. 2007 May;117(5):1155-66. doi: 10.1172/JCI31422.
Zotero 插件